Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.
Pfizer’s COVID-19 Treatment Paxlovid Will No Longer Be Available For Emergency Use After This Date, FDA Revises Label
FDA revises emergency use authorization for Pfizer's Paxlovid, impacting distribution and treatment of mild-to-moderate COVID-19. Transitions from March 8.
Sarepta Therapeutics’ Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.
Why Is Gastrointestinal Disease-Focused Palisade Bio Stock Trading Higher Today?
Palisade Bio' PALI-2108, a promising therapy for ulcerative colitis, shows impressive preclinical efficacy. PALI shares surge 151%.
Hope for Kidney Cancer Patients, Merck’s Keytruda Cuts Risk Of Death By 38% Following Surgery
Results from Merck's Phase 3 KEYNOTE-564 trial. Keytruda, an adjuvant treatment for renal cell carcinoma, shows a 38% improvement in overall survival at 57.2 months.
Dutch Health Tech Firm Philips Stops US Sales Of Respiratory Devices Under Finalized Consent Decree Over Device Recall
Philips' Q4 earnings and FDA settlement insights. Learn about the consent decree, actions, future plans for Philips Respironics in the U.S. International services remain unaffected. Philips' 2024 forecasts and financial outlook.
Bristol Myers’ Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.
Merck’s Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
Merck's Keytruda results in treating high-risk urothelial carcinoma. Discover statistically significant improvements in disease-free survival at ASCO GU Cancers Symposium 2024.
Why Is Precision Oncology-Focused Corbus Pharmaceuticals Stock Trading Higher Today?
Corbus Pharma's CRB-701 exhibits 43% ORR and 71% disease control in urothelial cancer trial.
Analyst Highlights ‘Rock Solid’ Data For Vera Therapeutics’ Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.